Welcome to LookChem.com Sign In|Join Free
  • or
Probucol Disuccinate is a di-substituted derivative of Probucol, an antilipemic agent used in the treatment of coronary artery disease. It has been shown to have lowering effects on HDL cholesterol levels.

216168-45-5

Post Buying Request

216168-45-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

216168-45-5 Usage

Uses

Used in Pharmaceutical Industry:
Probucol Disuccinate is used as a pharmaceutical agent for the treatment of coronary artery disease. It helps in lowering the levels of HDL cholesterol, which is beneficial in managing the condition.
Used in Cardiovascular Health:
Probucol Disuccinate is used as a cardiovascular health supplement to maintain healthy cholesterol levels. Its ability to lower HDL cholesterol levels makes it a potential candidate for managing and preventing cardiovascular diseases.

Check Digit Verification of cas no

The CAS Registry Mumber 216168-45-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,6,1,6 and 8 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 216168-45:
(8*2)+(7*1)+(6*6)+(5*1)+(4*6)+(3*8)+(2*4)+(1*5)=125
125 % 10 = 5
So 216168-45-5 is a valid CAS Registry Number.

216168-45-5Downstream Products

216168-45-5Relevant academic research and scientific papers

PROCESS FOR ISOLATING MONO-CARBOXY SUBSTITUTED PROBUCOL DERIVATES

-

Page/Page column 10-14, (2009/03/07)

A process for isolating a compound of formula (I) or a salt thereof, where X and R1 are as defined in the specification, from a mixture containing it, and the corresponding diacid and dihydroxy derivative, said process comprising (i) adding to an organic

Process for preparation of probucol derivatives

-

Page/Page column 3, (2008/06/13)

A method is described for the preparation of polymorphic forms of water-soluble derivatives of probucol compounds having the following formula where R1, R2, R3, R4, R5, R6, and Z′ are defined herein.

PROCESS FOR THE SEPARATION OF PROBUCOL DERIVATIVES

-

Page/Page column 21; 22-23; 25-26; 28-29; 32-33; 35-36; 38-41; 47, (2010/11/24)

Provided are methods for the separation of mono-substituted probucol derivatives from a mixture of both mono- and di-substituted probucol derivatives. In particular, methods are provided for the separation of mono-carboxy substituted probucol derivatives

Process for preparation of probucol derivatives

-

Page/Page column 3-4, (2008/06/13)

A method is described for the preparation of polymorphic forms of water-soluble derivatives of probucol compounds having the following formula where R1, R2, R3, R4, R5, R6, Z and Z′ are defined herein.

Process of preparing esters and ethers of probucol and derivatives thereof

-

Page/Page column 17, (2008/06/13)

Provided are methods for manufacturing compounds of Formula I wherein all substituents are described herein.

Process for preparation of probucol derivatives

-

Page/Page column 3; 4, (2008/06/13)

A method is described for the preparation of polymorphic forms of water-soluble derivatives of probucol compounds having the following formula where R1, R2, R3, R4, R5, R6, Z and Z′ are defined herein.

PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF

-

Page/Page column 49, (2008/06/13)

Provided are methods for manufacturing compounds of Formula I wherein all substituents are described herein.

Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis

Meng, Charles Q.,Somers, Patricia K.,Rachita, Carolyn L.,Holt, Lisa A.,Hoong, Lee K.,Zheng,Simpson, Jacob E.,Hill, Russell R.,Olliff, Lynda K.,Kunsch, Charles,Sundell, Cynthia L.,Parthasarathy, Sampath,Saxena, Uday,Sikorski, James A.,Wasserman, Martin A.

, p. 2545 - 2548 (2007/10/03)

A series of novel phenolic compounds has been discovered as potent inhibitors of TNF-α-inducible expression of vascular cell adhesion molecule-1 (VCAM-1) with concurrent antioxidant and lipid-modulating properties. Optimization of these multifunctional agents led to the identification of 3a (AGI-1067) as a clinical candidate with demonstrated efficacies in animal models of atherosclerosis and hyperlipidemia.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 216168-45-5